

IASLC

JULY 31 - AUGUST 4, 2009

MOSCONE WEST

SAN FRANCISCO, USA

2ND ANNOUNCEMENT SCIENTIFIC PROGRAMME UPDATE




I A S L C

13th World Conference on Lung Cancer

July 31 - August 4, 2009 San Francisco, CA

IMPORTANT DATES

Abstract Submission	OPEN
Online Registration	OPEN
Abstract Submission Deadline	13 March 2009
Author Notification of Acceptance	24 April 2009
Late Breaking Abstract Submission Deadline	15 May 2009
Early Registration Deadline	15 May 2009
Hotel Reservation Deadline	15 June 2009
Regular Registration Deadline	19 June 2009



**UCDAVIS
CANCER CENTER**

2009worldlungcancer.org

www.iaslc.org



INVITED SPEAKERS

*Confirmed speakers as of February 16, 2009, please visit the Conference website for the most current information

- | | | |
|---|---|---|
| Raymond Pierre Abratt , South Africa | David Carbone , USA | Tracey Evans , USA |
| Bonnie Addario , USA | Michele Carbone , USA | William K. Evans , Canada |
| Alex A. Adjei , USA | Desmond N. Carney , Ireland | Enriqueta Felip , Spain |
| Sam H. Ahmedzai , UK | Janine Cataldo , USA | Laurie Fenton-Ambrose , USA |
| Kathy S. Albain , USA | David Cella , USA | Hiran C. Fernando , USA |
| Steven Albelda , USA | Alex Yuang-Chi Chang , Singapore | John K. Field , UK |
| Michael Alberts , USA | Lucian R. Chirieac , USA | Raja Flores , USA |
| Nasser Altorki , USA | Noah C. Choi , USA | Kwun M. Fong , Australia |
| Christine Ambrosone , USA | Hak Choy , USA | Jesme Fox , UK |
| Rodrigo Arriagada , France | David C. Christiani , USA | Wilbur Franklin , USA |
| Hisao Asamura , Japan | Helen Clayson , UK | Haian Fu , USA |
| Fumihiko Asano , Japan | Lisa M. Coussens , USA | Takehiko Fujisawa , Japan |
| Philippe Astoul , France | James Cox , USA | Masahiro Fukuoka , Japan |
| Rick Avila , USA | Jeffrey Crawford , USA | Shirish Gadgeel , USA |
| Paul Baas , Netherlands | Lucio Crino , Italy | David Gandara , USA |
| Ramsey D. Badawi , USA | John J. Crowley , USA | Laurie E. Gaspar , USA |
| David L. Ball , Australia | Michael Cullen , UK | Stefano Gasparini , Italy |
| Allan Balmain , USA | Walter J. Curran, Jr. , USA | Ulrich Gatzemeier , Germany |
| Carlos Barrios , Brasil | Thomas D'Amico , USA | Oliver Gautschi , Switzerland |
| John Beamis , USA | Janet Dancey , Canada | Adi Gazdar , USA |
| Heinrich Becker , Germany | Philippe Dartevelle , France | Kim R. Geisinger , USA |
| David G. Beer , USA | Paul De Leyn , Belgium | Vaseilios Georgoulis , Greece |
| Chandra P. Belani , USA | Ruggero De Maria , Italy | Mark Geraci , USA |
| Steven A. Belinsky , USA | Dirk De Ruyscher , Netherlands | Paul Germonpré , Belgium |
| Gerold Bepler , USA | Todd Demmy , USA | Giuseppe Giaccone , Netherlands |
| Andrea Bezjak , Canada | Philip Andrew Dennis , USA | Stanton Glantz , USA |
| Cindy Billingham , UK | Alain Depierre , France | Bonnie S. Glisson , USA |
| James F. Bishop , Australia | Frank C. Detterbeck , USA | Tuncay Goksel , Turkey |
| Jeffrey Bogart , USA | Jean-Yves Douillard , France | Peter Goldstraw , UK |
| Philip Bonomi , USA | Carolyn M. Dresler , USA | Glen Goss , Canada |
| Alain Borczuk , USA | Sarita Dubey , USA | Ramaswamy Govindan , USA |
| Michael J. Boyer , Australia | Steven M. Dubinett , USA | Richard Gralla , USA |
| Julie Brahmer , USA | Rafal Dzadziosko , Poland | Vanesa Gregorc , Italy |
| Elisabeth Brambilla , France | Wilfried Eberhardt , Germany | Cesare Gridelli , Italy |
| John Britton , UK | John Eckhardt , USA | Steven Grunberg , USA |
| Lukas Bubendorf , Switzerland | Eric S. Edell , USA | Dominique H. Grunenwald , France |
| Paul A. Bunn, Jr. , USA | Martin J. Edelman , USA | Nasser Hanna , USA |
| Charles Butts , Canada | Lawrence H. Einhorn , USA | Peter Harper , UK |
| Royce F. Calhoun , USA | Jeremy Erasmus , USA | David H. Harpole , USA |
| Ross Camidge , USA | Armin Ernst , USA | Biao He , USA |
| Federico Cappuzzo , Italy | David Ettinger , USA | Claudia I. Henschke , USA |

INVITED SPEAKERS CONTINUED

Roy S. **Herbst**, USA
 Felix **Herth**, Germany
 Paul J. **Hesketh**, USA
 John **Heymach**, USA
 Fred R. **Hirsch**, USA
 Vera **Hirsh**, Canada
 Waun Ki **Hong**, USA
 Sally **Hunsberger**, USA
 Yukito **Ichinose**, Japan
 Norihiko **Ikeda**, Japan
 Yuichi **Ishikawa**, Japan
 David M. **Jablons**, USA
 Thierry M. **Jahan**, USA
 Vinay **Jain**, USA
 Pasi A. **Janne**, USA
 Jacek **Jassem**, Poland
 James R. **Jett**, USA
 Bruce **Johnson**, USA
 David H. **Johnson**, USA
 Kirk **Jones**, USA
 Daniel **Karp**, USA
 Harubumi **Kato**, Japan
 Tomoya **Kawaguchi**, Japan
 Paul **Keall**, USA
 Dorothy M K **Keefe**, Australia
 Robert **Keith**, USA
 Steven M. **Keller**, USA
 Karen **Kelly**, USA
 Robert **Kerlan**, USA
 Kemp H. **Kernstine**, USA
 Keith **Kerr**, UK
 Shaf **Keshavjee**, Canada
 Fadlo R. **Khuri**, USA
 Edward S. **Kim**, USA
 Hedy **Kindler**, USA
 Kazuma **Kishi**, Japan
 Ritsuko **Komaki**, USA
 Feng-Ming **Kong**, USA
 Paris **Kosmidis**, Greece
 Syrigos **Kostantinos**, Greece

Mark **Krasna**, USA
 Mark **Krasnik**, Denmark
 Robert **Kratzke**, USA
 Mark **Kris**, USA
 Lee **Krug**, USA
 Kaoru **Kubota**, Japan
 Omer **Kucuk**, USA
 Jasleen **Kukreja**, USA
 Hideo **Kunitoh**, Japan
 Noriaki **Kurimoto**, Japan
 Mario **Lacouture**, USA
 Stephen **Lam**, Canada
 Rodney J. **Landreneau**, USA
 Corey J. **Langer**, USA
 Primo N. **Lara, Jr.**, USA
 Derick **Lau**, USA
 Quynh **Thu Le**, USA
 Cecile **Le Pechoux**, France
 Lorriana **Leard**, USA
 J. Jack **Lee**, USA
 Jin Soo **Lee**, South Korea
 Pyng **Lee**, Singapore
 Natasha **Leighl**, Canada
 Ann **Leung**, USA
 Rogerio C. **Lilenbaum**, USA
 Ilona **Linnoila**, USA
 Scott **Lippman**, USA
 Billy W. **Loo**, USA
 Bo **Lu**, USA
 Thomas **Lynch**, USA
 Homer **Macapinlac**, USA
 Fergus **Macbeth**, UK
 Philip C. **Mack**, USA
 Michael **MacManus**, Australia
 Sumithra J. **Mandrekar**, USA
 Christian **Manegold**, Germany
 Jenny **Mao**, USA
 Pierre P. **Massion**, USA
 Douglas J. **Mathisen**, USA
 Julien **Mazieres**, France

Annette **McWilliams**, Canada
 Atul **Mehta**, USA
 Matthew L. **Meyerson**, USA
 David **Midthun**, USA
 Vincent A. **Miller**, USA
 York E. **Miller**, USA
 Bernard **Milleron**, France
 John **Minna**, USA
 Tetsuya **Mitsudomi**, Japan
 Tony **Mok**, Hong Kong
 Laureano **Molins**, Spain
 Luis **Montuenga**, Spain
 Elizabeth H. **Moore**, USA
 Cesar **Moran**, USA
 Françoise **Mornex**, France
 James L. **Mulshine**, USA
 Nevin **Murray**, Canada
 Kristiaan **Nackaerts**, Belgium
 Yasushi **Nagata**, Japan
 Kazuhiko **Nakagawa**, Japan
 Yasuo **Nakajima**, Japan
 Yuko **Nakayama**, Japan
 Ronald B. **Natale**, USA
 Joseph R. **Nevins**, USA
 Andrew G. **Nicholson**, UK
 Silvia **Novello**, Italy
 Kenneth **O'Byrne**, Ireland
 William **Pao**, USA
 Purvish **Parikh**, India
 Jae-Gahb **Park**, South Korea
 Keunchil **Park**, South Korea
 Harvey I. **Pass**, USA
 Bernward **Passlick**, Germany
 Ugo **Pastorino**, Italy
 Edward F. **Patz, Jr.**, USA
 Nick **Pavlakis**, Australia
 Luis **Paz-Ares**, Spain
 Roman **Perez-Soler**, USA
 Iver **Petersen**, Germany
 Robert **Pirker**, Austria

Katherine MW **Pisters**, USA
 Jerome **Posner**, USA
 Pieter **Postmus**, Netherlands
 Anil **Potti**, USA
 Allan **Price**, UK
 Joe B. **Putnam, Jr.**, USA
 Elisabeth **Quoix**, France
 David **Raben**, USA
 Suresh **Ramalingam**, USA
 Ramón **Rami-Porta**, Spain
 Scott **Ramsey**, USA
 Karen **Reckamp**, USA
 Mary W. **Redman**, USA
 Noemi **Reguart**, Spain
 Umberto **Ricardi**, Italy
 James R. **Rigas**, USA
 Bruce **Robinson**, Australia
 Victor **Roggli**, USA
 Rafael **Rosell**, Spain
 Jack A. **Roth**, USA
 Charles **Rudin**, USA
 Valerie **Rusch**, USA
 Nagahiro **Saijo**, Japan
 Ravi **Salgia**, USA
 Montserrat **Sanchez-Cespedes**, Spain
 Alan B. **Sandler**, USA
 Regina **Santella**, USA
 Giorgio V. **Scagliotti**, Italy
 Joan H. **Schiller**, USA
 Suresh **Senan**, Netherlands
 John **Seng**, USA
 David K. **Shelton**, USA
 Frances A. **Shepherd**, Canada
 Kiyoshi **Shibuya**, Japan
 Jill M. **Siegfried**, USA
 George **Simon**, USA
 Mark **Socinski**, USA
 Jean-Charles **Soria**, France
 Gabriella **Sozzi**, Italy
 Alex **Spira**, USA

Margaret **Spitz**, USA
 Simon **Spivack**, USA
 Rolf A. **Stahel**, Switzerland
 Ian **Stratford**, UK
 David **Sugarbaker**, USA
 Robert **Suh**, USA
 Yan **Sun**, China
 Thomas G. **Sutedja**, Netherlands
 Kenji **Suzuki**, Japan
 Stephen **Swensen**, USA
 Stephen G. **Swisher**, USA
 Eva **Szabo**, USA
 Ken **Takahashi**, Japan
 Takashi **Takahashi**, Japan
 Miquel **Taron**, Spain
 Satoshi **Teramukai**, Japan
 Pierre **Theodore**, USA
 Luc **Thiberville**, France
 Sumitra **Thongprasert**, Thailand
 Robert **Timmermann**, USA
 Antonio J. **Torres Garcia**, Spain
 William D. **Travis**, USA
 Alain **Tremblay**, Canada
 Ming Sound **Tsao**, Canada
 Masahiro **Tsuboi**, Japan
 Ryosuke **Tsuchiya**, Japan
 Hirohiko **Tsujii**, Japan
 Andrew T. **Turrisi**, USA
 Eric **Vallieres**, USA
 Paul **van Houtte**, Belgium
 Rob J. **van Klaveren**, Netherlands
 Jan P. **van Meerbeeck**, Belgium
 Paul **van Schil**, Belgium
 Nico van **Zandwijk**, Australia
 Johan **Vansteenkiste**, Belgium
 Nicholas **Vogelzang**, USA
 Everett E. **Vokes**, USA
 Hiromi **Wada**, Japan
 Heather **Wakelee**, USA
 Garrett L. **Walsh**, USA

Maria **Werner Wasik**, USA
 Shun-Ichi **Watanabe**, Japan
 Walter **Weder**, Switzerland
 Howard (Jack) **West**, USA
 Ignacio I. **Wistuba**, USA
 Antoinette J. **Wozniak**, USA
 Yi-Long **Wu**, China
 Nise H **Yamaguchi**, Brazil
 Nobuyuki **Yamamoto**, Japan
 Pan-Chyr **Yang**, Taiwan
 David F. **Yankelevitz**, USA
 Yosef **Yarden**, Israel
 Kazuhiro **Yasufuku**, Canada
 Yasushi **Yatabe**, Japan
 Sue S. **Yom**, USA
 Ken Y. **Yoneda**, USA
 Liang **You**, USA
 Riad N **Younes**, Brazil
 Rex C. **Yung**, USA
 Maureen **Zakowski**, USA
 Petr **Zatloukal**, Czech Republic
 Benny Chung-Ying **Zee**, China
 Xiuyi **Zhi**, China

SCIENTIFIC PROGRAMME • SATURDAY, AUGUST 1

Preliminary Programme as of February 16, please visit the Conference website for the most current information

FRIDAY, JULY 31

07:00 - 11:00 YOUNG INVESTIGATOR'S SESSION

The Future of Lung Cancer: Better Detection, Better Targeting

BETTER DETECTION

Finding the Lung Cancer Stem Cell – John Minna, *USA*

Improvements in Early Detection – James Jett, *USA*

New Imaging Tools for Diagnosis and Therapy Monitoring in Lung Cancer – Homer Macapinlac, *USA*

Non-invasive Mediastinal Staging – Stefano Gasparini, *Italy*

BETTER TARGETING

Gene Expression Profiling for Diagnosis and Therapy – Anil Potti, *USA*

Pharmacogenomic based Strategies for Diagnosis and Therapy – Louis Pas Arez, *Spain*

Biomarkers for Targeted Agents – John Heymach, *USA*

Trials Designs for Biomarker Assessment – Cindy Billingham, *UK*

SATURDAY, AUGUST 1

07:00 - 08:00 MEET THE PROFESSOR SESSIONS

Medical Oncology

MTP1 Lung Cancer Vaccines – Glen Goss, *Canada*

MTP2 Oligometastatic Disease: Solitary Brain, Adrenal – Philippe Dartevelle, *France*

Pulmonary

MTP3 Interventional Bronchoscopic Techniques in The Treatment of Lung Cancer – Thomas Sutedja, *Netherlands*

Biology

MTP4 Molecular Pathogenesis of Lung Cancer and its Precursor Lesions – Adi Gazdar, *USA*

MTP5 Oncopolitics – James Mulshine, *USA*

Pathology

MTP6 Large Cell Carcinoma – Keith Kerr, *UK*

Surgery

MTP7 Maximizing Perioperative Outcome after Neoadjuvant Therapy – Stephen Swisher, *USA*

Supportive Care

MTP8 Comprehensive Pain Management in the Advanced Lung Cancer Patient – Sam Ahmedzai, *UK*

Radiation Oncology

MTP9 Thoracic Radiotherapy Issues in SCLC – Andrew Turrisi, *USA*

Imaging

MTP10 New Treatment Modalities for Mesothelioma – TBA

08:30 - 10:00 PLENARY SESSION

P1 Personalized Therapy

Chairs: David Gandara, *USA*; Joseph Nevins, *USA*

- Overview – David Gandara, *USA*
- Biomarker Development – Harvey Pass, *USA*
- Emerging Methodologies – Fred Hirsch, *USA*
- Gene Signatures – Joseph Nevins, *USA*
- Pharmacogenomic Approaches – Giorgio Scagliotti, *Italy*

10:30 - 12:00 INTERACTIVE GRAND ROUNDS SESSION

GR1 Stage IIIA N2: 2003 versus 2009

Participants: Paul van Houtte, *Belgium*; Eric Vallieres, *USA*; Kathy Albain, *USA*

10:30 - 12:00 EDUCATION AND MINI SYMPOSIA SESSIONS

Medical Oncology

E1 EGFR Pathway

Chairs: Mark Kris, *USA*; Alex Yuang-Chi Chang, *Singapore*

- Biology of the EGF Pathway – Yosef Yarden, *Israel*
- Management of Toxicities of Anti-Angiogenic/Anti-EGFR Agents – Roman Perez-Soler, *USA*
- State of the Art of Clinical Research with Monoclonal Antibodies – Jean-Yves Douillard, *France*

M1 Novel Targets Beyond EGFR and VEGFR

Chairs: Sarita Dubey, *USA*; Giuseppe Giaccone, *USA*

- Src as a Target – TBA
- m-Tor Inhibitors – Lucio Crino, *Italy*
- HSP Inhibitors – Kenneth O’Byrne, *Ireland*
- HDAC Inhibitors – Lee Krug, *USA*
- Pro-apoptotic Agents – Rolf Stahel, *Switzerland*

Pulmonary

E2 Minimally Invasive Non-Surgical NSCLC Staging

Chairs: Michael Alberts, *USA*; Stefano Gasparini, *Italy*

- The Merits of Traditional Bronchoscopic Transbronchial Needle Aspiration – Stefano Gasparini, *Italy*
- The Advantages of Endobronchial Ultrasound Guided Needle Aspiration – Heinrich Becker, *Germany*
- Endoscopic Ultrasound Guided Needle Biopsy: Complementary or First Line? – TBA
- Electromagnetic Navigation Guided Biopsy of Mediastinal Lymph Nodes. The Latest Technology – Felix Herth, *Germany*

Biology

E3 Chemoprevention

Chairs: Ugo Pastorino, *Italy*; TBA

- Lung Cancer Chemoprevention – Waun Ki Hong, *USA*
- Chinese Traditional Herbal Medicine and Chemoprevention – Mei-Lin Liao, *China*
- Emerging Models for Lung Carcinogenesis – Luis Montuenga, *Spain*

M2 Angiogenesis in Lung Cancer

Chairs: Christian Manegold, *Germany*; Alan Sandler, *USA*

- Tumor Hypoxia, Angiogenesis and Lung Cancer – Joan Schiller, *USA*
- Predictive Plasma Biomarker Profiles – Suresh Ramalingam, *USA*
- Therapeutic Combinations with Bevacizumab – Antoinette Wozniak, *USA*
- Role of Anti-Angiogenic TKI’s – Heather Wakelee, *USA*
- Clinical Factors in Selecting Patients for Anti-Angiogenic Therapy – Alan Sandler, *USA*

Pathology

M3 Pathological Diagnosis and Molecular Analysis of Small and Cytological Specimens

Chairs : Kim Geisinger, *USA*; Elisabeth Brambilla, *France*

- Histopathological Diagnosis on Frozen Examination – Lucian Chirieac, *USA*
- FNA Diagnosis – Lukas Bubendorf, *Switzerland*
- Assessment of Cytological Samples – Maureen Zakowski, *USA*
- Gene Copy Number and Genetic Instability – Iver Petersen, *Germany*
- Assessment of Invasion Before Surgery – Alain Borczuk, *USA*

SCIENTIFIC PROGRAMME • SATURDAY, AUGUST 1

Radiation Oncology**E4 Preclinical and Translational Studies in Lung Cancer Radiotherapy**

Chairs: David Raben, *USA*; Michael MacManus, *Australia*

- Aurora Kinase Inhibitor + Radiation for NSCLC – Bo Lu, *USA*
- Radiation Sensitivity and EGFR Biology – Implication in of EGFR Targeting – David Raben, *USA*
- PARP Inhibitor and Radiation – Ian Stratford, *UK*
- PET FLT – Michael MacManus, *Australia*

Prevention**E5 Targets for Chemoprevention**

Chairs: Nico van Zandwijk, *Australia*; Ignacio Wistuba, *USA*

- Inflammatory Proteins – Eva Szabo, *USA*
- IGF-1R Pathway – Fadlo Khuri, *USA*
- EGFR Pathway – York Miller, *USA*
- COX/LOX Inhibition – Jenny Mao, *USA*

M4 Tobacco Control

Chairs: Carolyn Dresler, *USA*; Janine Cataldo, *USA*

- Challenges of Tobacco Control in the US – Stanton Glantz, *USA*
- Tobacco Control Strategies in Europe – John Britton, *UK*
- Asian Tobacco Epidemic – Xiuyi Zhi, *China*
- Tobacco Control in South America – Nise Yamaguchi, *Brazil*
- Smoking Cessation in Asia – Jae-Gahb Park, *South Korea*

Supportive Care**M5 Controlling Adverse Effects of Treatment in Lung Cancer**

Chairs: Paul Hesketh, *USA*; Tomoya Kawaguchi, *Japan*

- Mucositis – Dorothy Keefe, *Australia*
- Emesis – Steven Grunberg, *USA*
- Fatigue – John Eckhardt, *USA*
- Cutaneous Toxicities – Mario Lacouture, *USA*

Surgery**E6 Optimal Therapy for Resectable Lung Cancer**

Chairs: Jack Roth, *USA*; Riad Younes, *Brazil*

- Neoadjuvant Chemotherapy – Steven Keller, *USA*
- Adjuvant Chemotherapy – Nasser Hanna, *USA*
- Pharmacogenomic Approaches – Rafael Rosell, *Spain*
- Predictive Markers – David Harpole, *USA*

Imaging**E7 Early Detection of Lung Cancer**

Chairs: Johan Vansteenkiste, *Belgium*; James Jett, *USA*

- Current Screening Trial Results (NLST, ELCAP, NELSON) – James Jett, *USA*
- Evaluation of Indeterminate Pulmonary Nodule/ GGO – Yasuo Nakajima, *Japan*
- Unexpected Findings on Screening Studies – Stephen Swensen, *USA*

14:30 - 16:00 PROFFERED PAPER AND POSTER DISCUSSION SESSIONS**16:30 - 18:00 INTERACTIVE GRAND ROUNDS SESSION****GR2 Adjuvant Chemotherapy: Stage Specific Discussion**

Chairs: Thierry Jahan, *USA*; James Bishop, *Australia*

Participants: Mark Socinski, *USA*; Raymond Pierre Abratt, *South Africa*; Joseph Putnam, *USA*

14:30 - 16:00 EDUCATION AND MINI SYMPOSIA SESSIONS**Medical Oncology****E8 VEGF pathway**

Chairs: Christian Manegold, *Germany*; Phil Bonomi, *USA*

- Biology of VEGFR Pathway – Vinay Jain, *USA*
- State of the Art of Clinical Research with Monoclonal Antibodies – David Johnson, *USA*
- State of the Art of Clinical Research with Small VEGF-TKI Molecules – TBA

- Management of Toxicities of Anti-Angiogenic/Anti-EGFR agents – John Heymach, *USA*

M6 Established Targets for NSCLC – Multi-Targeted Agents and Drug Combinations

Chairs: Roy Herbst, *USA*; Kazuhiko Nakagawa, *Japan*

- Multiple Tyrosine Kinase Inhibitors: What is the Rationale and the Clinical Evidence? – Chandra P. Belani, *USA*
- IGFR Pathway : Rationale and Inhibitors – Ross Camidge, *USA*
- Vascular Disrupting Agents (VDA): Emerging Role in NSCLC – Primo Lara, *USA*
- EGFR Pathway Inhibition: Emerging Predictive Markers – Thomas Lynch, *USA*
- DNA Repair Mechanism – Jean Charles Soria, *France*

M7 Progress with Neoadjuvant Window of Opportunity Trials

Chairs: Vaseilios Georgoulas, *Greece*; Purvish Parikh, *India*

- NeoAdjuvant Therapy – Insight into Perceptions – Purvish Parikh, *India*
- Standardizing Acquisition Parameters and Imaging Quality – David F. Yankelevitz, *USA*
- Development of Image Processing Tools for Drug Response Evaluation – Rick Avila, *USA*
- NeoAdjuvant Trial with RAD001 – Fadlo Khuri, *USA*

E9 Neoadjuvant Chemotherapy Trials in Lung Cancer

Chairs: Alain Depierre, *France*; Martin Edelman, *USA*

- Neoadjuvant Chemotherapy Past and Present European Trials – Bernard Milleron, *France*
- S9900 Trial Update, Mature Analysis – Katherine Pisters, *USA*
- Surgical Issues with Neoadjuvant Trials – Is the Surgical Risk Increased? – Kemp Kernstine, *USA*

Pulmonary

M8 Novel Technologies

Chairs: Paul Germonpre, *Belgium*; TBA

- Electronic Nose – Annette McWilliams, *Canada*
- Optical Coherence Tomography – Stephen Lam, *Canada*
- Autofluorescence-Reflectance Imaging – Norihiko Ikeda, *Japan*
- Narrow Band Imaging – Kiyoshi Shibuya, *Japan*
- Confocal Micro-Endosocopy – Luc Thiberville, *France*

Biology

M9 Predictive or Prognostic Factors in Chemotherapy

Chairs: Rafael Rosell, *Spain*; Bruce Johnson, *USA*

- ERCC1 and RRM1 – Predictive vs. Prognostic Roles – George Simon, *USA*
- BRCA1 Gene and Sensitivity to Lung Cancer Chemotherapy – Rafael Rosell, *Spain*
- TS as a Marker of Sensitivity to Anti-Folates – Giorgio Scagliotti, *Italy*
- KRAS as a Marker of Chemoresistance – Ming Tsao, *Canada*
- Genomic-Derived Signatures of Cisplatin and Pemetrexed Sensitivity – Joseph Nevins, *USA*

Surgery

M10 Emerging Operative Techniques in Early Stage Lung Cancer

Chairs: Xiu-Yi Zhi, *China*; Shaf Keshavjee, *Canada*

- Techniques of VATS Resections for Lobectomy, Segmentectomies, and Lymph Node Dissections and Their Results in 2009: Who are the Candidates, When Do You Not Do This? – Thomas D'Amico, *USA*
- Evidence for the use of Sublobar vs Lobar Resections for the Medically Operable Lung Cancer Patient: A Complete Review of the Literature with Most Recent Results – Shun-ichi Watanabe, *Japan*
- Intraoperative Techniques for the Prevention of Positive Margins: Intraoperative Radiation Techniques and Results, Intraoperative Cytology Utility, Lesion size Guiding the Type of Operation – Sue Yom, *USA*

SCIENTIFIC PROGRAMME • SATURDAY, AUGUST 1

- Management of the Patient with Multiple Synchronous/Metachronous Pulmonary Lesions: Lobectomies, Segmentectomies, Wedge Resections, Simultaneous, Staged, How much Staging? – Kenji Suzuki, *Japan*

Prevention**M11 Women and Lung Cancer**

Chairs: Laurie Gaspar, *USA*; Enriqueta Felip, *Spain*

- Smoking Cessation Strategies in Women – Carolyn Dresler, *USA*
- Genetic Susceptibility to Lung Cancer in Women – Julie Brahmer, *USA*
- Estrogen and Progesteron Receptors in Lung Cancer – Jill Siegfried, *USA*
- Sex as a Prognostic and Predictive Factor – Silvia Novello, *Italy*
- Clinical and Epidemiologic Features of Lung Cancer in Asian Females – Sumitra Thongprasert, *Thailand*

Radiation Oncology**M12 Debate – Stereotactic Radiotherapy for Stage I NSCLC: Should it be Regarded as the Standard of Care for Inoperable Tumors and Are We Ready to Replace Surgery?**

Chairs: Robert Timmermann, *USA* ; David Ball, *Australia*

- For STR in Inoperable Tumor – Robert Timmermann, *USA*
- Against SRT in Inoperable Tumors – David Ball, *Australia*
- For STR in Operable Tumors – Suresh Senan, *Netherlands*
- Against SRT in Operable Tumors – Paul van Schil, *Belgium*

Imaging**M13 Staging and Follow-up of Lung Cancer**

Chairs: David Shelton, *USA*; Ken Yoneda, *USA*

- Conventional Imaging (CT, MR) – Ann Leung, *USA*
- CT/PET Staging – Jeremy Erasmus, *USA*

- EBUS-EUS (pulmonary) – Kazuhiro Yasufuku, *Canada*
- Imaging Response and Surveillance (PET, CT) – Homer Macapinlac, *USA*
- Molecular Diagnostics and New Imaging Probes – Ramsey Badawi, *USA*

Mesothelioma**M14 New Insights in the Pathogenesis and Treatment of Malignant Mesothelioma**

Chairs: Raja Flores, *USA*; Nicholas Vogelzang, *USA*

- The Asbestos Threat: A World-Wide Overview of the Epidemiology of Asbestos Exposure – Ken Takahashi, *Japan*
- Non-Asbestos Related Mesothelioma: The Role of SV40 – Michele Carbone, *USA*
- Current MM Lab Studies and their Possible Translation – Robert Kratzke, *USA*
- Gene Therapy/Immunotherapy and Mesothelioma: Where Are We – Steven Albelda, *USA*

Biostatistics Session**M15 Statistical Issues in Drug Development**

Chairs: John Crowley, *USA*; Mary Redman, *USA*

- TBA – John Crowley, *USA*
- Phase I Designs for Identifying a Biologically Optimal Dose – Sumithra Mandrekar, *USA*
- Dose Escalation Trials Based on a Molecularly Targeted Endpoint – Sally Hunsberger, *USA*
- A Clinician's Perspective – Derick Lau, *USA*

SCIENTIFIC PROGRAMME • SUNDAY, AUGUST 2

SUNDAY, AUGUST 2

07:00 – 08:00 MEET THE PROFESSOR SESSIONS

Medical Oncology

MTP11 Bevacizumab Dosing and Duration – Christian Manegold, *Germany*

MTP12 Novel Cytotoxics in Small Cell – Vera Hirsh, *Canada*

MTP13 Systemic Treatment of Brain Metastasis in Lung Cancer – Corey Langer, *USA*

Pulmonary

MTP14 Management of Malignant Pleural Effusions – Philippe Astoul, *France*

Pathology

MTP15 Mesothelioma – Kirk Jones, *USA*

Biology

MTP16 Novel Signal Transduction Pathways – Giuseppe Giaccone, *USA*

MTP17 Molecular Biology and Pathology of Lung Adenocarcinomas – Yasushi Yatabe, *Japan*

Radiation Oncology

MTP18 Management of Oligometastasis: Should Patients with Limited Sites of Metastasis be Treated Aggressively? – Andrea Bezjak, *Canada*

MTP19 Current Status of Prophylactic Cranial Irradiation in SCLC – Cecile Le Pechoux, *France*

Mesothelioma

MTP20 Translational Research and Mesothelioma – Harvey Pass, *USA*

Supportive Care

MTP21 Neurological Complications of Lung Cancer and its Treatment – Jerome Posner, *USA*

08:30 – 10:00 PLENARY SESSION

P2 State of the Art

Chairs: Frances Shepherd, *Canada*; Masahiro Tsuboi, *Japan*

- Surgery – Masahiro Tsuboi, *Japan*
- Radiotherapy – Hak Choy, *USA*
- Chemotherapy – Everett Vokes, *USA*
- Targeted Therapy – Frances Shepherd, *Canada*

10:30 – 12:00 INTERACTIVE GRAND ROUNDS AND HIGHLIGHT OF THE DAY SESSIONS

GR3 Testing for Biomarker driven Therapy, (ERCC1 and EGFR)

Participants: Gerold Bepler, *USA*; Vincent Miller, *USA*; Janet Dancey, *Canada*

HOD1 HIGHLIGHT OF THE DAY

David Ettinger, *USA*

10:30 – 12:00 EDUCATION AND MINI SYMPOSIA SESSIONS

Medical Oncology

M16 Clinical Trial Designs with Biomarkers to Incorporate or Validate Clinical or Lab Selection

Chairs: John Crowley, *USA*; Elisabeth Quoix, *France*

- Front Line Studies Using Clinical Parameters for EGFR-TKIs – Tony Mok, *Hong Kong*
- EGFR in Prospective Studies – Rafal Dziadziusko, *Poland*
- ERCC1 and RRM1 Studies in Advanced Disease – Gerold Bepler, *USA*
- Prospective Studies with Proteomics – Vanesa Gregorc, *Italy*
- Histology As A Selection Factor for Treatment – Shirish Gadgeel, *USA*

SCIENTIFIC PROGRAMME • SUNDAY, AUGUST 2

Pulmonary**E10 Management of Malignant Pleural Effusions**

Chairs: Philippe Astoul, *France*; John Beamis, *USA*

- Surgical Management of Malignant Pleural Effusions – Raja Flores, *USA*
- Thoracoscopy – John Beamis, *USA*
- PleurX Catheter Placement – Alain Tremblay, *Canada*
- Implanted Port Reservoir for Pleural Drainage – Ken Yoneda, *USA*

Biology**E11 Genetics and Epigenetics in Lung Carcinogenesis**

Chairs: Ravi Salgia, *USA*; Adi Gazdar, *USA*

- DNA Methylation Markers in Lung Cancer – TBA
- Somatic Mutations in Lung Cancer – Monserrat Sanchez-Caspedes, *Spain*
- Molecular Changes in Invasion, Tumor Progression and Metastasis – Wilbur Franklin, *USA*

M17 Identifying Cancer Stem Cells

Chairs: David Jablons, *USA*; Nobuyuki Yamamoto, *Japan*

- Stem Cell Population in Mouse Lung Cancer – Allan Balmain, *USA*
- Prognostic Markers
 - Wnt Signaling – Liang You, *USA*
 - Hedgehog – TBA
 - Notch – Noemi Reguart, *Spain*
- Upcoming Therapeutics: Preclinical to Clinical – Biao He, *USA*
- Lung Cancer Stem Cells and Their Application to Future Prevention Research -John Minna, *USA*

Mesothelioma**E12 Pleural Mesothelioma : Bridging the Present with the Future**

Chairs: Hedy Kindler, *USA*; Tuncay Goksel, *Turkey*

- Biomarkers: What Do We Know and How Do We Use Them? – Bruce Robinson, *Australia*

- What is the Standard Treatment of MPM? First and Second Line – Paul Baas, *Netherlands*
- The Challenges of New Drug Development for Mesothelioma – Hedy Kindler, *USA*

Cost Effectiveness**E13 Cost Effectiveness of Lung Cancer Care**

Chair: William Evans, *Canada*

- Cost Studies in Lung Cancer-What's the Purpose? – James Bishop, *Australia*
- The Use, Cost and Cost-Effectiveness of Chemotherapy in NSCLC – Scott Ramsey, *USA*
- Molecular Targeted Therapy – Can We Afford It? – William Evans, *Canada*

Pathology**M18 Adenocarcinoma: Multidisciplinary Classification**

Chairs: TBA; Kirk Jones, *USA*

- New Classification Concept – William Travis, *USA*
- Compartment Concept for Lung Cancer Pathogenesis – Ignacio Wistuba, *USA*
- Molecular Profiling of Morphotype – Takashi Takahashi, *Japan*
- In Situ, Invasion, Extension as Prognostic Factors – TBA

Supportive Care**M19 Bringing Quality of Life Assessment into the Mainstream of Lung Cancer Management**

Chairs: Natasha Leighl, *Canada*; Jin Soo Lee, *South Korea*

- Which Tool of Measurement? – Peter Harper, *UK*
- Defining Clinically Relevant Changes in QOL Measurements – David Cella, *USA*
- Improving Compliance in QOL Measurement With Web-Based Tools – James Rigas, *USA*
- Long-term QOL Following Surgery for NSCLC – Pierre Theodore, *USA*

Surgery

E14 Emerging Options for Therapy in Early Stage NSCLC

Chairs: Jasleen Kukreja, *USA*; Hiromi Wada, *Japan*

- Competing Non-Surgical Therapies for Early Stage Non-Small Cell Lung Cancer: SBRT – Yasushi Nagata, *Japan*
- Radiofrequency Ablation – Hiran Fernando, *USA*
- Choosing the Right Therapy for the Right Patient – Mark Krasna, *USA*

Prevention

E15 Chemoprevention: Past, Present and Future

Chairs: Desmond Carney, *Ireland*; TBA

- Chemoprevention in the 21st Century – TBA
- High Throughput Screening and the Selection of Natural Compounds for Prevention – Haiyan Fu, *USA*
- Retinoids in Cancer Therapy and Chemoprevention: Promise Meets Resistance – TBA

Advocacy

M20 Advocacy and Survivorship in Lung Cancer

Chairs: Selma Schimmel, *USA*; Bonnie Addario, *USA*

- National Lung Cancer Partnership: The US Approach – Joan Schiller, *USA*
- Roy Castle Foundation : The European Approach – Jesme Fox, *UK*
- Lung Cancer Alliance: How to Succeed in Increasing the Awareness about Lung Cancer – Laurie Fenton-Ambrose, *USA*
- Bonnie J. Addario Lung Cancer Foundation: Bridging to the Future – Bonnie Addario, *USA*
- The Role of Media in Increasing the Awareness About Lung Cancer – John J. Seng, *USA*

Radiation Oncology

M21 Implementing Radiation and Systemic Therapy for Stage III Non-Small Cell Lung Cancers

Chairs: Paul van Houtte, *Belgium*; Walter Curran, Jr., *USA*

- What Should be the Standard of Care Outside Clinical Trials? – Walter Curran, Jr., *USA*
- Radiation Volume Considerations in Combined Modality Therapy – Laurie Gaspar, *USA*
- When is Concurrent Chemo-Radiation Not the Treatment of Choice in Inoperable Stage III Disease? – Fergus Macbeth, *UK*
- Integration of Novel Targeted Therapy to Combined Chemoradiation – What Agent and What Settings? – Quynh-Thu Le, *USA*

14:30 - 16:00 PROFFERED PAPER AND POSTER DISCUSSION SESSIONS

16:30 - 18:00 INTERACTIVE GRAND ROUNDS SESSION

GR4 Debate: Monoclonal Antibodies versus Tyrosine Kinase Inhibitors: Pros and Cons

Chairs: Yan Sun, *China*; Petr Zatloukal, *Czech Republic*

Participants: Michael Boyer (Monoclonal Antibody), *Australia*; Ron Natale (TKI's), *USA*

16:30 - 18:00 EDUCATION AND MINI SYMPOSIA SESSIONS

Medical Oncology

M22 Open Challenges in the Management of Advanced NSCLC

Chairs: Syrigos Kostantinos, *Greece*; Edward Kim, *USA*

- Mechanisms of Drug Resistance with Cytotoxics – Miquel Taron, *Spain*
- Maintenance with Cytotoxics – Karen Kelly, *USA*
- Maintenance with EGFR Agent – Jacek Jassem, *Poland*
- Maintenance with VEGF Agent – Roy Herbst, *USA*
- Role of Radiotherapy in the Management of Metastatic Disease – Dirk De Ruyscher, *Netherlands*

SCIENTIFIC PROGRAMME • SUNDAY, AUGUST 2

M23 SCLC: An Orphan Disease?

Chairs: Bonnie Glisson, *USA*; Pieter Postmus, *Netherlands*

- Epidemiology of SCLC – Ramaswamy Govindan, *USA*
- Small Cell Lung Cancer : Current Standards – Kaoru Kubota, *Japan*
- Targeted Therapies : The Available Evidence – Bruce Johnson, *USA*
- Potential New Targets for SCLC – Charles Rudin, *USA*

Pulmonary**M24 The Role of the Chest Physician in a Multidisciplinary Lung Cancer Clinic**

Chairs: James Jett, *USA*; Png Lee, *Singapore*

- Differential Diagnoses – Kazuma Kishi, *Japan*
- PET For Diagnosis and Staging – Johan Vansteenkiste, *Belgium*
- Preoperative Evaluation of Pulmonary Function – Kwun Fong, *Australia*
- Pulmonary Complications in the Treatment of Lung Cancer – Julien Mazieres, *France*
- Interventional Bronchoscopy – Png Lee, *Singapore*

Biology**M25 Lung Cancer Biomarkers**

Chairs: John Field, *UK*; Lorriana Leard, *USA*

- Lung Carcinogenesis Detected by Exhaled Breath Approaches – Simon Spivack, *USA*
- The Latest SNPs and CHIPS in Lung Cancer – Mark Geraci, *USA*
- DNA Methylation – Steven Belinsky, *USA*
- Proteomics – Pierre Massion, *USA*
- Plasma DNA as a Biomarker for Lung Cancer Detection and Prognosis – Gabriella Sozzi, *Italy*

M26 Molecular Predictors of Response and Resistance to EGFR Tyrosine Kinase Inhibitors (TKI's)

Chairs: Vincent Miller, *USA*; Tony Mok, *Hong Kong*

- Comparative Frequency of EGFR and KRAS Mutations in Japanese and US Populations – Tetsuya Mitsudomi, *Japan*
- Resistance Factors to EGFR TKIs – William Pao, *USA*
- Second-Generation EGFR Inhibitors and Combinations – Ulrich Gatzemeier, *Germany*
- Prediction of Benefit from EGFR TKIs by Proteomic Analysis of Pre-treatment Serum – David Carbone, *USA*
- EGFR Immunohistochemistry: Prediction of Benefit from Gefitinib – Federico Cappuzzo, *Italy*

M27 Emerging Fields of Lung Cancer Research

Chairs: Ryosuke Tsuchiya, *Japan*; Lisa Coussens, *USA*

- Molecular Pathogenesis of Lung Cancer – John D. Minna, *USA*
- COX2 in lung Cancer – Karen Reckamp, *USA*
- Mouse Models of Lung Cancer – Ilona Linnoila, *USA*
- Identification and Expansion of the Tumorigenic Lung Cancer Stem Cell Population – Ruggero De Maria, *Italy*

Surgery**M28 Locally Advanced Lung Cancer: Role of Surgery & Mediastinal Evaluation**

Chairs: Wilfried Eberhardt, *Germany*; Royce Calhoun, *USA*

- What is the Definition of “Resectable N2 Disease”? – Surgeon’s View – Walter Weder, *Switzerland*
- What is the Definition of “Resectable N2 disease”? – Medical Oncologist’s View – Wilfried Eberhardt, *Germany*
- Role of Pneumonectomy – Rodney Landreneau, *USA*
- Surgical Complications for Pre-Operative Therapy – Dominique H. Grunenwald, *France*

M29 Specialized Surgical Expertise: Indications, Results

Chairs: Douglas Mathisen, *USA*; Stephen Swisher, *USA*

- Vascular Sleeve Resections – TBA
- Involvement of the T-spine, including Pancoast Tumor – Garret Walsh, *USA*
- Guidelines for Intraoperative Lymph Node Staging – Bernward Passlick, *Germany*
- Extent of Surgery for Synchronous/Metachronous Pulmonary Lesions – Hisao Asamura, *Japan*

Prevention

M30 Novel Agents in Clinical Trials for Prevention

Chair: Robert Keith, *USA*; Masahiro Fukuoka, *Japan*

- Iloprost Study – Robert Keith, *USA*
- Rapamycin and Rapamycin Analogs – Philip Dennis, *USA*
- Zileuton – Omer Kucuk, *USA*
- New Avenues for Chemoprevention – Steven Dubinett, *USA*

E16 Modeling Approaches to Mortality Reduction

Chair: James Mulshine, *USA*; Claudia Henschke, *USA*

- Expectation of Potential Outcomes with "Best Practice" Screening – Claudia Henschke, *USA*
- Outcome Measures in the National Lung Screening Trial – Ugo Pastorino, *Italy*
- Defining the "High Risk Cohort" for Lung Cancer Screening – Rob J. van Klaveren, *Netherlands*

Radiation Oncology

M31 Debate –Role of Adjuvant Radiation Therapy in Resected N2 Non-Small Cell Lung Cancer Patients

Chairs: Umberto Ricardi, *Italy*; Cecile Le Pechoux, *France*

- Pro: Françoise Mornex, *France*
- Con: Noah Choi, *USA*

Imaging

E17 Image Guided Procedures

Chairs: Robert Kerlan, *USA*; Jeremy Erasmus, *USA*

- Percutaneous Biopsies – Elizabeth Moore, *USA*
- Radiofrequency Ablation – Robert Suh, *USA*
- Stenting and Embolization – Robert Kerlan, *USA*

SCIENTIFIC PROGRAMME • MONDAY, AUGUST 3

MONDAY, AUGUST 3

07:00 – 08:00 MEET THE PROFESSOR SESSIONS

Medical Oncology

MTP22 Management of Thymoma – Tracey Evans, *USA*

MTP23 Special Populations: Elderly and PS2 – Cesare Gridelli, *Italy* (Elderly); Rogerio Lilenbaum, *USA* (PS2)

Pulmonary

MTP24 Evaluation of Solitary Pulmonary Nodules – David Midthun, *USA*

MTP25 Bronchial Intraepithelial Neoplasia and Early Central Airway Lung Cancer: Screening, Diagnosis and Treatment – Rex Yung, *USA*

Biology

MTP26 Gene-Directed Therapy in Lung Cancer – Jack Roth, *USA*

Mesothelioma

MTP27 The Extended Debate on Surgery

Chair: Valerie Rusch, *USA*

- Surgery in Mesothelioma: YES – David Sugarbaker, *USA*
- Surgery in Mesothelioma: NO – Nick Pavlakis, *Australia*

Pathology

MTP28 Preneoplastic Lesions – Andrew Nicholson, *UK*

Supportive Care

MTP29 Comprehensive Supportive Care in the Patient with Mesothelioma – Helen Clayson, *UK*

Radiation Oncology

MTP30 Radiotherapy for Malignant Pleural Mesothelioma: Thymic Tumors: Where is the Evidence? – Allan Price, *UK* (Mesothelioma); TBA (Thymic Tumors)

Imaging

MTP31 Image Guidance in Judging Therapeutic Response – David Shelton, *USA*

08:30 – 10:00 PRESIDENTIAL SYMPOSIUM

PRS Presidential Address and Selected Proffered Papers

Chairs: David Jablons, *USA*; Nagahiro Saijo, *Japan*

- State of the IASLC – Nagahiro Saijo, *Japan*

10:30 – 12:00 INTERACTIVE GRAND ROUNDS AND HIGHLIGHT OF THE DAY SESSIONS

GR5 Therapy for Early Stage NSCLC with Poor Lung Function: Surgical vs. Non-Surgical

Participants: Brachytherapy – Yuko Nakayama, *Japan*; Stereotactic Radiotherapy – Suresh Senan, *Netherlands*; Surgery – Royce Calhoun, *USA*

HOD2 HIGHLIGHT OF THE DAY

Nevin Murray, *Canada*

10:30 – 12:00 PROFFERED PAPER SESSIONS

12:15 – 12:45 ISLAC BUSINESS MEETING

SCIENTIFIC PROGRAMME • TUESDAY, AUGUST 4

TUESDAY, AUGUST 4

07:00 – 08:00 MEET THE PROFESSOR SESSIONS

Medical Oncology

MTP32 Ethnic Differences in Chemotherapy Toxicities and Outcomes – Alex Yuang-Chi Chang, *Singapore*

MTP33 Mechanisms of Drug Resistance to Targeted Agents – Pasi Janne, *USA*

MTP34 Limited Surgical Resection and Local Radiation Therapy for High Risk NSCLC
– Jeffrey Bogart, *USA*

MTP35 Ethnic Considerations in EGFR Biology and Clinical Parameters – Keunchil Park, *South Korea*

Surgery

MTP36 Emerging Endoscopic Staging Techniques
– Todd Demmy, *USA*

Radiation Oncology

MTP37 Proton Beam Radiotherapy – James Cox, *USA*

Pulmonary

MTP38 Physiologic Evaluation of Patients with Lung Cancer for Lung Resection – Kristiaan Nackaerts, *Belgium*

Biology

MTP39 New Insights: Oncogenes and Tumor Suppressor Genes in Lung Carcinogenesis – Gabriella Sozzi, *Italy*

Pathology

MTP40 Mediastinal Tumors – Cesar Moran, *USA*

MTP41 Should Treatment of NSCLC be Histology-Based? – Lawrence Einhorn, *USA*

08:30 – 10:00 PLENARY SESSION

P3 Implementation of IASLC Revised Staging System

Chairs: Desmond Carney, *Ireland*; Valerie Rusch, *USA*

- Overview – Peter Goldstraw, *UK*
- Pathologic Implications – Elisabeth Brambilla, *France*
- Imaging Implications – Edward Patz, *USA*
- Taking the New Staging System into the Clinic – Valerie Rusch, *USA*

10:30 – 12:00 INTERACTIVE GRAND ROUNDS AND HIGHLIGHT OF THE DAY SESSIONS

GR6 Pre-operative vs. Post-operative Chemotherapy for Early Stage NSCLC

Participants: Pre-Operative Therapy – Katherine Pisters, *USA*; Post-Operative Therapy – Keunchil Park, *South Korea*

HOD3 HIGHLIGHT OF THE DAY

Michael Cullen, *UK*

10:30 – 12:00 EDUCATION AND MINI SYMPOSIA SESSIONS

Medical Oncology

E18 Adjuvant Therapies in Early Disease Management

Chairs: Heather Wakelee, *USA*; Harubumi Kato, *Japan*

- Systemic Chemotherapy : The Current Evidence – Howard “Jack” West, *USA*
- Is There Still a Role for Adjuvant Radiotherapy? – Rodrigo Arriagada, *France*
- Vaccines as Adjuvant Treatment – Charles Butts, *Canada*
- Antifolate in the Adjuvant Setting – Yukito Ichinose, *Japan*

SCIENTIFIC PROGRAMME • TUESDAY, AUGUST 4

M32 Supportive Care Optimization as a Target

Chairs: Peter Harper, *UK*; Paul Hesketh, *USA*

- Antiemetics – Paul Hesketh, *USA*
- Control of Pain – Richard Gralla, *USA*
- Anemia – Corey Langer, *USA*
- Bone Metastases – Carlo Barrios, *Brazil*
- Dyspnea – Lorriana Leard, *USA*

Pulmonary**E19 Image Guided Biopsy/ Novel Technologies**

Chairs: Armin Ernst, *USA*; Eric Edell, *USA*

- Virtual Bronchoscopic Navigation – Fumihiko Asano, *Japan*
- Electromagnetic Navigation – Atul Mehta, *USA*
- Endoscopic Ultrasonography for Peripheral Lung Lesions – Noriaki Kurimoto, *Japan*
- EBUS/EUS for Mediastinal Staging – Takehiko Fujisawa, *Japan*

M33 Cutting Edge in OMICS Research for Lung Cancer

Chairs: Takashi Takahashi, *Japan*; David Beer, *USA*

- SNP Arrays and Oncogene Discovery – Matthew Meyerson, *USA*
- Proteomics – David Carbone, *USA*
- MicroRNA Signatures – Pan-Chyr Yang, *Taiwan*
- Genomic Signatures – Anil Potti, *USA*
- Gene Expression in the Airways – Alex Spira, *USA*

Biology**M34 Signal Transduction Inhibitors – Biology and Activity**

Chairs: Ronald Natale, *USA*; Jin Soo Lee, *South Korea*

- Signal Transduction Overview – Paul Bunn Jr., *USA*
- C-Met Inhibitors – Ravi Salgia, *USA*
- Src Inhibitors – Oliver Gautschi, *Switzerland*
- MEK Inhibitors – Alex Adjei, *USA*
- IGF-1R Inhibitors – Luis Paz-Ares, *Spain*

Pathology**M35 Lights and Shadows in the Staging of Lung Cancer**

Chairs: James Jett, *USA*; Peter Goldstraw, *UK*

- Lung Cancer Staging: Latest Revision – Frank Detterbeck, *USA*
- How New Staging Affects Surgical Perspectives – Ramon Rami-Porta, *Spain*
- Pleural Invasion – Victor Roggli, *USA*
- Multiple Tumor Nodules – Yuichi Ishikawa, *Japan*

Supportive Care**M36 Update on Hematopoietic Growth Factors in Lung Cancer Management**

Chairs: Jan van Meerbeek, *Belgium*; Vera Hirsh, *Canada*

- Clinical Use of the Erythropoietin Stimulating Agents: Defining the Benefits – Robert Pirker, *Australia*
- Clinical Use of the Erythropoietin Stimulating Agents: Defining the Risks – Paris Kosmidis, *Greece*
- Role of Myeloid Growth Factors in Lung Cancer – Jeffrey Crawford, *USA*

Surgery**E20 Mediastinal Restaging**

Chairs: Yi-Long Wu, *China*; Antonio Torres Garcia, *Spain*

- Imaging of the Mediastinum after Induction Therapy – Paul De Leyn, *Belgium*
- EBUS with or without EUS – Mark Krasnik, *Denmark*
- Repeat Mediastinoscopy – Laureano Molins, *Spain*

Prevention**M37 Risk Stratified Approaches to Prevention of Lung Cancer**

Chairs: Nico Van Zandwijk, *Australia*; Margaret Spitz, *USA*

- Chemoprevention of High Risk Patient Populations – Nico van Zandwijk, *Australia*
- Development of Molecular Risk Models for Lung Cancer – Margaret Spitz, *USA*

- Convergence Between Adjuvant and Prevention Approaches – Scott Lippman, *USA*
- Molecular Profiles of Risk Stratification on the Selenium Trial – Steven Belinsky, *USA*

Radiation Oncology

M38 Implementing Image Guided Radiation Therapy in Clinical Practice

Chairs: Paul Keall, *USA*; TBA

- The Role of PET Imaging for Radiation Treatment Planning and Adaptive Radiation Therapy – Feng-Ming Kong, *USA*
- Pitfalls of Strategies for Motion Management – William Loo, *USA*
- Intensity Modulated Radiation Therapy for Locally Advanced Tumor – Good or Bad – Ritsuko Komaki, *USA*
- The Status of Particle Beam Therapy for Lung Cancer – Hirohiko Tsujii, *Japan*
- Beyond IGRT – A Look To The Future – Maria Werner Wasik, *USA*

Biology

M39 Molecular Epidemiology of Lung Cancer

Chairs: Christine Ambrosone, *USA*; Kathy Albain, *USA*

- Overview: Molecular Epidemiology of Lung Cancer – Christine Ambrosone, *USA*
- Biomarkers of Polycyclic Aromatic Hydrocarbon – DNA Damage and Cigarette Smoke Exposure – Regina Santella, *USA*
- Role of EGFR pathway activation in Never Smoking Patients with Lung Cancer – Philip Mack, *USA*
- Polymorphisms of DNA Repair Genes and Tobacco-related Carcinogenesis – David Christiani, *USA*

Biostatistics

M40 Statistical Designs in the Bioinformatics Age

Chairs: Benny Chung-Ying Zee, *China*; Satoshi Teramukai, *Japan*

- Adaptive Designs Based on Biomarkers – Jack Lee, *USA*
- Phase III Trial Designs for Targeted Agents – Mary Redman, *USA*
- A Clinical Researcher's Perspective – Hideo Kunitoh, *Japan*

12:30 - 14:00 PROFFERED PAPERS AND POSTER DISCUSSION SESSIONS